Laboratorios Farmacéuticos Rovi, S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Laboratorios Farmacéuticos Rovi, S.A.
A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.
Spain’s Rovi is prioritizing European filing and filling preparations for its long-acting risperidone injectable, pushing back a prospective US regulatory submission until next year.
- Medical Devices
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Rovi Pharmaceuticals Laboratories